Welcome to our dedicated page for QUEST DIAGNOSTICS SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated filings document a public diagnostic information services company with common stock listed on the New York Stock Exchange under DGX. The company’s 8-K reports disclose operating results, guidance updates, investor presentation materials, dividends, share repurchase authorizations, senior unsecured debt issuance and other material agreements tied to its capital structure.
Proxy filings describe annual meeting proposals, director elections, board committee assignments, governance practices, executive compensation and the company’s strategy for diagnostic testing insights, healthcare-provider relationships, data assets, automation and artificial intelligence. The filing record also documents shareholder voting matters and formal changes in board composition.
Quest Diagnostics senior vice president Karthik Kuppusamy reported a mix of equity award activity and related share disposition. He acquired 6,200 shares of common stock on March 4, 2026 as stock issued in settlement of a performance stock award approved under Rule 16b-3(d). To cover tax withholding from this award, 2,628 shares of common stock at $204.86 per share were disposed of back to the issuer. After these transactions, he held 13,441 shares directly, plus additional indirect holdings of 358 shares by trust and 1,658 shares in a 401(k) plan, based on information from the plan administrator.
DGX files a Rule 144 notice to sell 3,878 common shares tied to restricted stock vesting on 02/23/2026.
The filing also reports recent sales by Michael Prevoznik of 1,111 shares on 02/19/2026 for $227,566.13 and 526 shares on 03/03/2026 for $109,265.98.
Catherine T. Doherty reported sales of Common Stock under a Form 144 notice. The excerpt lists three open-market transactions: 26,165 shares on 02/13/2026, 1,433 shares on 02/19/2026, and 632 shares on 03/03/2026. The broker listed is Fidelity Brokerage Services LLC.
Thomas P. Plewman reported sales of common stock via Form 144. The filing lists multiple dispositions: 5,662 shares (sale proceeds $1,155,048.00) on 02/10/2026, 958 shares (proceeds $196,227.14) on 02/19/2026, and 410 shares (proceeds $85,169.30) on 03/03/2026. The excerpt also shows 2,855 shares from a restricted stock vesting entry dated 02/23/2026.
Quest Diagnostics executive Catherine T. Doherty reported sales and related share dispositions of company stock. On March 3, 2026, she executed an open-market sale of 632 shares of common stock at $207.73 per share, leaving 67,122 shares held directly.
On March 2, 2026, 648 shares were disposed of at $204.86 per share to cover tax obligations tied to the vesting of restricted share units, and the sale activity was carried out under a pre-arranged Rule 10b5-1 trading plan. She also holds 4,502 shares indirectly through a company 401(k)/profit sharing plan.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported a Form 4 transaction involving common stock. On the reported date, he disposed of 869 shares at $204.86 per share in a tax-withholding transaction tied to the vesting of a prior restricted stock unit grant. This was a sale of shares to satisfy tax obligations rather than an open-market trade. After this transaction, he directly owned 27,041 shares of Quest Diagnostics common stock.
Quest Diagnostics senior vice president and general counsel Michael E. Prevoznik reported recent stock transactions. On March 3, he executed an open-market sale of 526 shares of common stock at $207.73 per share under a Rule 10b5-1 sales plan, leaving 37,557 shares held directly afterward. On March 2, 288 shares were disposed of at $204.86 per share to cover tax obligations from the vesting of restricted share units. He also has 5,737 shares held indirectly through company 401(k) and deferred compensation plans.
Quest Diagnostics CEO and President J. E. Davis reported two stock transactions in company common stock. He disposed of 2,968 shares at $204.86 per share to satisfy tax obligations from the vesting of a prior restricted share unit grant. He also completed an open-market sale of 10,000 shares at $212.52 per share under a pre-arranged Rule 10b5-1 sales plan. After these transactions, he directly holds 117,185 Quest Diagnostics shares.
Quest Diagnostics senior vice president Patrick Plewman reported two stock dispositions. He sold 410 shares of common stock in an open-market transaction at $207.73 per share under a Rule 10b5-1 sales plan he previously adopted.
He also disposed of 230 shares at $204.86 per share to cover tax obligations from the vesting of an earlier restricted share unit grant. After these transactions, he directly owns 15,198 shares of Quest Diagnostics common stock.
Quest Diagnostics senior vice president Karthik Kuppusamy disposed of 205 shares of common stock at $204.86 per share to cover tax obligations from vesting restricted share units. This tax-withholding transaction on March 2, 2026 was not an open-market sale. After the transaction, he held 9,869 shares directly, plus additional indirect holdings through a trust and the company’s 401(k) plan.